JP Morgan Chase’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.1K Buy
+500
New +$21.1K ﹤0.01% 6928

Other funds holding DFTX

JP Morgan Chase's DFTX Position: Q3 2026 in Review

JP Morgan Chase increased its Definium Therapeutics (DFTX) stake by 27% in Q3 2026, buying an estimated $3M and bringing the position to 337,191 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2616.

JP Morgan Chase first reported a position in DFTX in Q2 2021 and has held it in 22 quarters since. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • JP Morgan Chase held 337,191 shares of Definium Therapeutics worth $12.9M as of Q3 2026.
  • JP Morgan Chase bought 71,236 Definium Therapeutics shares in Q3 2026, an estimated $3M.
  • Definium Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #2616 holding.
  • JP Morgan Chase first reported a position in Definium Therapeutics in Q2 2021 and has held it in 22 quarters since.
  • 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.